Personalized Synthetic Long Peptide Vaccine

BIOLOGICAL3 trials

Sponsors

National Cancer Institute (NCI), Jaime Leandro Foundation for Therapeutic Cancer Vaccines

Conditions

Anatomic Stage IV Breast Cancer AJCC v8CancerInvasive Breast CarcinomaMetastatic Triple-Negative Breast CarcinomaSolid Tumor

Phase 1

A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors

Enrolling by invitationNCT05741242

Jaime Leandro Foundation for Therapeutic Cancer VaccinesCancer, Solid Tumor

Start: 2022-11-30End: 2029-01-31Target: 136Updated: 2026-01-15

Phase 2

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

RecruitingNCT03606967

National Cancer Institute (NCI)Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma

Start: 2021-04-13End: 2026-12-30Target: 86Updated: 2026-09-09

Unknown Phase

Expanded Access To Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors

Jaime Leandro Foundation for Therapeutic Cancer VaccinesCancer

Updated: 2026-01-15

Related Papers

Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients

Genome Medicine2024-11-1451 citations

A randomized phase II study of nab<i>-</i>paclitaxel + durvalumab + neoantigen vaccine versus nab-paclitaxel + durvalumab in metastatic triple-negative breast cancer (mTNBC).

Journal of Clinical Oncology2019-05-208 citations